Mizuho raised the firm’s price target on Immix Biopharma (IMMX) to $15 from $14 and keeps an Outperform rating on the shares. The firm cites the company’s improved cash position post the Q4 report for the target increase.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMX: